PGR and breast cancer: Currently, the FDA (USA—Food and Drug Administration) and CE IVD (Europe—In Vitro Diagnostics) approve a relatively small number of applications for the automatic evaluation of pathological features, such as the expressions of ER, PR, HER-2 and Ki-67 in breast cancer, and they have similar results to those obtained by a human evaluator [63,84].